<DOC>
	<DOCNO>NCT01822093</DOCNO>
	<brief_summary>Human Adenovirus-specific T-cells persist augment impair adenovirus immune response post allogeneic haematopoietic stem cell transplant , reduce requirement antiviral therapy without toxicity increase occurrence Graft Versus Host Disease . This Phase I/IIa open-label safety study , assess effect administer adenovirus-specific T-cells ( Cytovir ADV ) paediatric patient post haematopoietic stem cell transplant .</brief_summary>
	<brief_title>Safety Study ADV-specific T-cells Paediatric Patients Post Allo-HSCT</brief_title>
	<detailed_description />
	<criteria>Patients : 1 . Age 16 year younger 2 . Scheduled undergo allogeneic HSCT unrelated donor , mismatch unrelated donor , mismatch family donor haplo identical donor 3 . The subject ( legally acceptable representative ) must give informed consent ( assent subject â‰¥ 12 year ) . All subject parent guardian provide inform consent subject provide witness verbal assent 4 . Negative serology HIV 1 + 2 , HepB , HepC , Syphilis , hCG . Donors 1 . Meets requirement Directive 2004/23/EC amend UK statutory instrument pursuant therein 2 . Negative serology HIV 1 + 2 , HepB , HepC , Syphilis , hCG 3 . Passed medical assessment stem cell donation 4 . HdADV seropositive 5 . Signed informed consent 6 . Age 16 year old Patients 1 . Pregnant lactating female 2 . Coexisting medical problem would place patient significant risk death due GVHD sequela 3 . Human Immunodeficiency Virus ( HIV ) infection Donors 1 . Pregnant lactating female 2 . ( assessed prior apheresis ) Platelets &lt; 50x109/L</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>